Director Daniel S Janney Files Intent to Sell Additional $3.7M in Krystal Biotech Stock After Recent $10.1M Sale
KRYS has more than doubled off its 52-week low of $122.8.
Summary
Director Daniel S Janney has filed an intent to sell an additional $3.7 million in Krystal Biotech shares, following a recent sale of $10.1 million, indicating significant insider selling.
Key Events · Ownership and Investor Activity · KRYS
-
Director Files Intent to Sell
Daniel S Janney, a Director, filed a Form 144 indicating intent to sell 13,825 shares of common stock, valued at approximately $3.7 million.
-
Recent Significant Share Sale
The filing also reports that Daniel S Janney recently sold 37,895 shares, generating gross proceeds of approximately $10.1 million.
-
Cumulative Insider Selling
This intent to sell, combined with the recent sale, represents over $13.8 million in selling activity by a director, contributing to a pattern of insider distribution.
Analysis · KRYS · Life Sciences
This Form 144 filing indicates that Director Daniel S Janney intends to sell 13,825 shares of Krystal Biotech common stock, valued at approximately $3.7 million. This follows a reported sale of 37,895 shares by Janney, generating $10.1 million in gross proceeds, as disclosed within the same filing. The cumulative selling activity by a director, totaling over $13.8 million, signals a significant reduction in insider holdings and contributes to a broader pattern of insider distribution observed in recent months. Investors should monitor further insider transactions for continued sentiment.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KRYS was trading at $266.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $122.80 to $298.30. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.